(News Bulletin 247) – AB Science reported last night a case of ‘complete response’ in one of the patients treated in its phase I/II study in acute myeloid leukemia (AML).
One month after the first cycle of treatment, that is to say after three consecutive days of treatment with its product AB8939, the company says it has observed a ‘drastic’ reduction in leukemic cells.
The term ‘complete response’ applies when all signs of the disease have disappeared after the establishment of a treatment.
Remarkably, according to AB Science, this response was achieved at a very low dose of AB8939, and the patient also showed excellent tolerance, with no treatment-related toxicity.
At the request of the investigator, AB Science has authorized additional treatment cycles for this patient, again with a good response maintained, which means that a third cycle has been initiated.
For Professor Olivier Hermine, president of the scientific committee of AB Science and member of the Academy of Sciences, said, these preliminary clinical data ‘provide the most encouraging signs to
to date that AB8939 may be well suited for the treatment of high-risk relapsed/refractory AML’.
AML is a serious, life-threatening disease and is the most common cause of death among leukaemias, largely because patients develop drug resistance.
existing first-line drugs.
Listed on the Paris Stock Exchange, the AB Science share rose 5.2% after this announcement.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
